Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Puts Black Box Warning On Power Morcellators With Immediately-In-Effect Guidance

This article was originally published in The Gray Sheet

Executive Summary

FDA has followed through on the advice of its advisory panel by requiring new labeling for power morcellators used to treat uterine fibroids, emphasizing the procedure’s potential to spread cancer. FDA wants to restrict the power morcellation procedure to younger women who are interested in maintaining their ability to have children and who have been thoroughly informed of the risks.

Advertisement

Related Content

Power Morcellator Use Increases Cancer Risk, FDA Verifies
Ultrasonic Aspirator Guidance Requires Warning On Uterine Use
Dr. Amy Reed, Anti-Power Morcellator Activist, Dead At 44
Lawmakers Plan Bill In Response To GAO Power Morcellator Report
US FDA: Ultrasonic Tools Shouldn't Be Used For Uterine Surgery
FDA Issues Policy For Making Immediate Changes To Device Submission Guidelines

Topics

Advertisement
UsernamePublicRestriction

Register

MT033529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel